retatrutide trials weight loss (“reta”) is an experimental weight-loss drug currently in Phase 3 clinical trials. It's a once-weekly injection similar to Ozempic and Mounjaro—but more powerful. The reason comes down to how it works Retatrutide Promises Big Weight Loss,

Fighting a digital hydra The Pharmaceutical Task Group , an industry body representing organised pharmacy and manufacturing interests, views this underground trade as a direct violation of the laws protecting the South African public

2 This was a cohort study that analyzed administrative registers in Denmark from 2007 to 2021, Norway from 2010 to 2018, and Sweden from 2007 to 2021

Retatrutide is a triple-receptor agonist that activates GLP-1, GIP, and glucagon pathways simultaneously, making it the most potent injectable weight loss compound currently in advanced clinical development

Some common side effects of GLP-1 medications include: Nausea and vomiting Diarrhea Constipation Abdominal pain Loss of appetite Headaches Infection Irritation at the injection site Patients on GLP-1 therapies can also experience muscle loss or bone density loss with prolonged use, which can compound some of the natural physical changes that accompany menopause